Breakthrough innovations are creating new therapies, drugs and medical devices. With so many options, how do investors evaluate these technologies to decide which ones to put their money behind?
Join us in Halifax on Thursday, March 10, for an expert panel discussion on due diligence, investment, intellectual property (IP) protection, and how to increase value in your company to make it attractive to investors.
Emma Saffman, PhD, Patent Agent, BCF (www.bcf.ca) – Emma is an experienced patent agent specializing in IP since 2000. She practices in all areas of chemistry and life sciences, with a broad range of experience in Canadian, U.S., and foreign patent prosecution, strategic IP portfolio development and management, patentability and freedom-to-operate analysis, due diligence evaluations, and litigation support. She has represented a wide variety of clients, from individuals to multinational corporations, including start-ups, universities, research organizations, and pharmaceutical companies. Prior to joining private practice, Emma was director of IP at Neurochem Inc., where she managed and maintained the company's patent and trademark portfolios worldwide.
John Holyoake, DPhil, Vice-President, Bloom Burton & Co. (www.bloomburton.com) – As vice-president of Toronto-based Bloom Burton & Co., John’s responsibilities include M&A advisory and monetization planning, as well as conducting technical and commercial due diligence of companies across all healthcare sectors. His area of expertise spans early stage technologies to profitable healthcare services companies, with a focus on preclinical-stage biotechnology and the U.S. healthcare system. John has industry experience from the clinical stage oncology company TenX Biopharma and at the life sciences consulting group SHI Link. John obtained a master’s degree in biochemistry from the University of Oxford, received a doctorate from the same institution, then made the transition across the Atlantic for a post-doctoral research fellowship at The Hospital for Sick Children in Toronto.
Gordon Cheung, MD, Partner and Chief Medical Officer, Epic Capital Management Inc. (www.epiccapitalmanagement.ca) – As partner and chief medical officer of Epic Capital Management Inc., Gordon is focused on Epic’s Healthcare franchise. A well-known interventional neuroradiologist, he has spent 50 per cent of his time investing in private healthcare companies over the last 10 years. He is currently also the clinical director of MRI and CT at CML HealthCare. Gordon is a founding partner of several companies, including Sentinelle Medical, TUC Managed IT Solutions, Excelion Technology and Perimeter Medical Imaging.
Thursday, March 10, 2016
9:00 am - 10:00 am (light breakfast from 8:30 am - 9:00 am)
Innovacorp Enterprise Centre
1344 Summer Street, Halifax
RSVP to Charmaine at firstname.lastname@example.org or 902.424.8674 x 1502 by Tuesday, March 8.
Note to our Cape Breton friends: We’re live-casting this session to a group gathered in Cape Breton at Navigate Startup House, 37 Nepean Street, Sydney; click here to let our team there (aka Bob Pelley!) know you’re coming to the Sydney webcast.